Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||EE8492 / 2||- / -|
Administered by: Other Purchased by: ??
Symptoms: Abortion spontaneous, Maternal exposure during pregnancy, SARS-CoV-2 test
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: FOLIC ACID
Preexisting Conditions: Medical History/Concurrent Conditions: Hypothyroidism; Pregnancy (The patient had 2 previous normal pregnancies with no miscarriages); Pregnancy (Patient no longer pregnant at the time of reporting.)
Diagnostic Lab Data: Test Name: COVID-19 virus test; Test Result: Negative ; Comments: No - Negative COVID-19 test
CDC 'Split Type': GBPFIZER INC2021692452
Write-up: Miscarriage; Maternal exposure during pregnancy; This is a spontaneous report from a contactable consumer. This is a report received from the Regulatory Agency (RA). The regulatory authority report number is GB-MHRA-WEBCOVID-202106111926336710-K9ZIE, Safety Report Unique Identifier is GB-MHRA-ADR 25461365. A 37-year-old pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Lot Number: EE8492), via an unspecified route of administration on 17Mar2021 as dose 2, single for COVID-19 immunisation. The patient''s medical history included pregnancy and Patient no longer pregnant at the time of reporting, hypothyroid. The patient had 2 previous normal pregnancies with no miscarriages. The patient did not had symptoms associated with COVID-19 and not enrolled in clinical trial. The patient was not currently breastfeeding. Historical vaccination included bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) as dose 1 on an unspecified date for COVID-19 immunization. Concomitant medications included 400 ug of folic acid (FOLIC ACID) taken for vitamin supplementation. The patient has not tested positive for COVID-19 since having the vaccine. The patient received vaccine at 2 weeks after conception and her pregnancy was anembronic. On an unspecified date, the patient reported maternal exposure during pregnancy and had miscarriage at 10 weeks. The patient underwent lab tests and procedures which included COVID-19 virus test: negative. The outcome of the event maternal exposure during pregnancy was unknown. The outcome of the event miscarriage was recovering. No follow-up attempts are possible. No further information is expected.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166